Study Shows New Diagnostic Test From Roche Can Help ID Which HPV+ Patients are at Higher Risk for Cervical Cancer

When a woman tests positive for HPV, it is vital to quickly determine whether or not she is likely to develop cervical cancer. In this segment, Dr. Carolyn Kay, Medical Affairs Leader in Cervical Cancer Solutions at Roche Diagnostics discusses a new study published in the “International Journal of Cancer” (Sep 18, 2021) that found that using Roche Diagnostics’ FDA approved CINtec PLUS Cytology dual-stain biomarker technology as a triage test can help clinicians determine who needs immediate follow-up and who would benefit from further observation and screening, a much less invasive approach.

Dr. Carolyn Kay is an obstetrics and gynecology physician with special interests in cervical cancer, reproductive health and the incorporation of digital technology to address the unmet needs in women’s health. She earned her undergraduate degree at Bryn Mawr College and her medical degree at the State University of New York – Upstate Medical University. She completed her obstetrics and gynecology residency at the Hofstra Northwell School of Medicine in New Hyde Park, NY. She is currently the Medical Affairs Leader in cervical cancer solutions at Roche Diagnostics.